基质金属蛋白酶与肝纤维化关系的研究进展

戈宏焱; 张仕华

doi:10.3969/j.issn.1001-5256.2017.03.037

基质金属蛋白酶与肝纤维化关系的研究进展

DOI: 10.3969/j.issn.1001-5256.2017.03.037

1. 内蒙古民族大学附属医院内蒙古民族大学临床医学院消化内科
2. 内蒙古民族大学

基金项目:

内蒙古自然科学基金面上项目(2015MS0805)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2036
- HTML全文浏览量: 44
- PDF下载量: 539
- 被引次数: 0
出版历程
- 收稿日期: 2016-11-14
- 出版日期: 2017-03-20

Research advances in association between matrix metalloproteinases and liver fibrosis

Department of Gastroenterology, Affiliated Hospital of Inner Mongolia University for the Nationalities, Clinical Medical College of Inner Mongolia University for the Nationalities

Research funding:

摘要

摘要: 各种原因所致的肝损伤均可导致肝纤维化的发生,是慢性肝病向肝硬化转变的病理过程。肝纤维化的形成是由于细胞外基质的合成增加和降解减少导致。而细胞外基质主要由基质金属蛋白酶降解,基质金属蛋白酶在肝纤维化的进展、诊治过程中起着至关重要的作用。综述了基质金属蛋白酶与肝纤维化的关系。
- 肝硬化 /
- 基质金属蛋白酶类 /
- 综述
Abstract: Liver injury caused by various reasons can lead to the occurrence of liver fibrosis, which is the pathological process from chronic liver disease to liver cirrhosis.Liver fibrosis is caused by the increased synthesis and reduced degradation of extracellular matrix (ECM) .ECM is mainly degraded by matrix metalloproteinases (MMP) , and therefore, MMP play an important role in the progression and diagnosis/treatment of liver fibrosis.This article reviews the research advances in the association between MMP and liver fibrosis.
- liver cirrhosis /
- matrix metalloproteinases /
- review

HTML全文

参考文献(33)

[1]BATALLER R, BRENNER DA.Liver fibrosis[J].J Clin Invest, 2005, 115 (2) :209-218.

[2]DUARTE S, BABER J, FUJII T, et al.Matrix metalloproteinases in liver injury, repair and fibrosis[J].Matrix Biol, 2015, 44-46:147-156.

[3]ROBERT S, GICQUEL T, VICTONI T, et al.Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis[J].Biosci Rep, 2016, 36 (4) :e00360.

[4]NIE QH, DUAN GR, LUO XD, et al.Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis[J].World J Gastroenterol, 2004, 10 (1) :86-90.

[5]EBRAHIMI H, NADERIAN M, SOHRABPOUR AA.New concepts on pathogenesis and diagnosis of liver fibrosis;a review article[J].Middle East J Dig Dis, 2016, 8 (3) :166.

[6]KOCABAYOGLU P, LADE A, LEE YA, et al.β-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis[J].J Hepatol, 2015, 63 (1) :141-147.

[7]FAN TT, HU PF, WANG J, et al.Regression effect of hepatocyte nuclear factor 4αon liver cirrhosis in rats[J].J Dig Dis, 2013, 14 (6) :318-327.

[8]MURPHY FR, ISSA R, ZHOU X, et al.Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition implications for reversibility of liver fibrosis[J].J Biol Chem, 2002, 277 (13) :11069-11076.

[9]GOMIS-RUTH FX.Structural aspects of the metzincin clan of metalloendopeptidases[J].Mol Biotechnol, 2003, 24 (2) :157-202.

[10]EGEBLAD M, WERB Z.New functions for the matrix metalloproteinases in cancer progression[J].Nat Rev Cancer, 2002, 2 (3) :161-174.

[11]TOKITO A, JOUGASAKI M.Matrix metalloproteinases in non-neoplastic disorders[J].Int J Mol Sci, 2016, 17 (7) :1178.

[12]JIA HZ, PENG XJ.Effect of matrix metalloproteinases in keratoconus[J].Int Eye Sci, 2016, 16 (9) :1644-1647. (in Chinese) 贾洪真, 彭秀军.基质金属蛋白酶对圆锥角膜的影响[J].国际眼科杂志, 2016, 16 (9) :1644-1647.

[13]MURPHY G, STANTON H, COWELL S, et al.Mechanisms for pro matrix metalloproteinase activation[J].Apmis, 1999, 107 (1-6) :38-44.

[14]BREW K, NAGASE H.The tissue inhibitors of metalloproteinases (TIMPs) :an ancient family with structural and functional diversity[J].Biochim Biophys Acta, 2010, 1803 (1) :55-71.

[15]BREYNAERT C, de BRUYN M, ARIJS I, et al.Genetic deletion of tissue inhibitor of metalloproteinase-1/TIMP-1 alters inflammation and attenuates fibrosis in dextran sodium sulphate induced murine models of colitis[J].J Crohns Colitis, 2016, 10 (11) :1336-1350.

[16]HERNANDEZ-GEA V, FRIEDMAN SL.Pathogenesis of liver fibrosis[J].Annu Rev Pathol, 2011, 6:425-456.

[17]ENDO H, NIIOKA M, SUGIOKA Y, et al.Matrix metalloproteinase-13 promotes recovery from experimental liver cirrhosis in rats[J].Pathobiology, 2011, 78 (5) :239-252.

[18]FALLOWFIELD JA, MIZUNO M, KENDALL TJ, et al.Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis[J].J Immunol, 2007, 178 (8) :5288-5295.

[19]ONOZUKA I, KAKINUMA S, KAMIYA A, et al.Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice[J].Biochem Biophys Res Commun, 2011, 406 (1) :134-140.

[20]SAFADI R, FRIEDRMAN SL.Hepatic fibrosis-role of hepatic stellate cell activation[J].Med Gen Med, 2002, 4 (3) :27-27.

[21]CAWSTON T, CARRERE S, CATTERALL J, et al.Matrix metalloproteinases and TIMPs:properties and implications for the treatment of chronic obstructive pulmonary disease[J].Novartis Found Symp, 2001, 234:205-218.

[22]QIAO Z, LI Y, LU H, et al.Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma[J].World J Surg Oncol, 2013, 11:1.

[23]IIMURO Y, NISHIO T, MORIMOTO T, et al.Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat[J].Gastroenterology, 2003, 124 (2) :445-458.

[24]KANDASAMY AD, CHOW AK, ALI MA, et al.Matrix metalloproteinase-2 and myocardial oxidative stress injury:beyond the matrix[J].Cardiovasc Res, 2010, 85 (3) :413-423.

[25]ZOU LL, LIU R, LIU H, et al.Effect of agonists and inhibitorsof matrix metalloproteinases on expression of matrix metall-oproteinase 1/2 and collagen I in human scleral fibroblas[J].Chin J Ophthalmol and Otorhinolaryngol, 2013, 13 (2) :91-95. (in Chinese) 邹蕾蕾, 刘睿, 刘红, 等.MMPs激动剂和抑制剂对人巩膜成纤维细胞MMP1/2以及Ⅰ型胶原表达的作用研究[J].中国眼耳鼻喉科杂志, 2013, 13 (2) :91-95.

[26]KOONTONGKAEW S, AMOMPHIMOLTHAM P, MONTHANPISUT P, et al.Fibroblasts and extracellular matrix differently modulate MMP activation by primary and metastatic head and neck cancer cells[J].Med Oncol, 2012, 29 (2) :690-703.

[27]NAGASE H, VISSE R, MURPHY G.Structure and function of matrix metalloproteinases and TIMPs[J].Cardiovasc Res, 2006, 69 (3) :562-573.

[28]HELALY GF.Differences in circulating MMP-9 levels with regard to viral load and AST:ALT ratio between chronic hepatitis B and Cpatients[J].Br J Biomed Sci, 2011, 68 (1) :38-42.

[29]RAMACHANDRAN P, IREDALE JP.Liver fibrosis:a bidirectional model of fibrogenesis and resolution[J].QJM, 2012, 105 (9) :813-817.

[30]LIU J, CHENG X, GUO Z, et al.Truncated active human matrix metalloproteinase-8 delivered by a chimeric adenovirus-hepatitis B virus vector ameliorates rat liver cirrhosis[J].PLoS One, 2013, 8 (1) :e53392.

[31]SILLER-LOPEZ F, SANDOVAL A, SALGADO S, et al.Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis[J].Gastroenterology, 2004, 126 (4) :1122-1133.

[32]YANG SW, LEE SM, CHOI EY, et al.Matrix metalloproteinase‐1 induces cleavage of exogenous alphab-crystallin transduced by a cell‐penetrating peptide[J].J Cell Biochem, 2011, 112 (9) :2454-2462.

[33]KUO TK, HUNG SP, CHUANG CH, et al.Stem cell therapy for liver disease:parameters governing the success of using bone marrow mesenchymal stem cells[J].Gastroenterology, 2008, 134 (7) :2111-2121, e1-e3.

施引文献

资源附件(0)

访问统计